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Background: Thrombotic thrombocytopenic Purpura (TTP) defined as ADAMTS-13 (A Disintegrin And Metalloprotease
with ThromboSpondin type 1 domain 13) activity <10 % is a rare aetiology of thrombocytopenia during pregnancy,
although the precise incidence is unknown. During pregnancy, the diagnosis of TTP is crucial as it has high
feto-maternal morbidity-mortality and requires urgent plasma exchange. The purpose of this study was to assess
the incidence of TTP retrospectively and to describe case presentations and follow-up.
Methods: A monocentric retrospective study (2008–2009) was conducted among pregnant women followed in a
tertiary care obstetrical unit who experienced at least one episode of severe thrombocytopenia (platelets ≤75 G/L)
during 2008 and 2009. In cases of uncertain aetiology of thrombocytopenia, ADAMTS-13 activity was assessed by
the full length technique.
Results: Among 8,908 deliveries over the 2 year period, 79 women had a platelet count nadir ≤75 G/L. Eighteen
had a known aetiology of thrombocytopenia and 11 were lost to follow-up. Among 50 remaining patients,
ADAMTS-13 activity was undetectable (<5 %) in 4, consistent with the diagnosis of TTP. Platelet count spontaneously
normalized in 3 patients after delivery. None presented focal cerebral involvement. Three of the four, who were
primipara patients, had a sustained severe deficiency in the absence of anti-ADAMTS-13 antibodies, and ADAMTS-13
gene sequencing indicated a constitutive deficiency. The fourth, a multipara patient, had an acquired, auto-immune
TTP. Placental pathology in the three primipara patients showed severe and non-specific ischemic lesions. Two patients
lost their babies shortly after birth. In subsequent pregnancies in these two patients, prophylactic plasma infusion
initiated early with increasing volume throughout pregnancy prevented TTP relapse, improved placental pathology,
and led to normal delivery.
Conclusions: The prevalence of TTP among thrombocytopenic pregnant women is high, up to 5 % in a tertiary unit.
Platelet count normalization after delivery does not eliminate TTP. Clinicians should be aware of TTP during pregnancy,
and, even if assessed retrospectively, ADAMTS-13 assessment is of particular importance for identifying patients with
congenital TTP. In these patients, preventive plasma infusion and/or exchange can dramatically improve foetal
prognosis, resulting in successful childbirth.
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Thrombotic thrombocytopenic purpura (TTP) is a rare,
life-threatening, thrombotic microangiopathy (TMA)
characterized by severe deficiency in A Disintegrin And
Metalloprotease with ThromboSpondin type 1 domain
13 (ADAMTS-13). This von Willebrand factor (vWF)
cleaving protease deficiency is due either to autoantibodies
directed against the protein in the acquired form of the
disease, or to biallelic mutations of the encoding gene in
the inherited form (also termed Upshaw-Schulman syn-
drome) [1]. In TTP, vWF and platelet-rich thrombi in small
arterial vessels lead to mechanical haemolytic anaemia and
thrombocytopenia with ischaemic injury of organs, prefer-
entially in the brain and heart, which determines severity
of the disease [1, 2]. Pregnancy is a known trigger of TTP;
one precipitant might be that ADAMTS-13 activity physio-
logically decreases during pregnancy, while its substrate,
vWF, increases [3–5]. Within pregnancy-related diseases,
TTP can mimic other TMA such as Haemolysis Elevated
Liver enzymes Low Platelet (HELLP) syndrome [6, 7]. It is
critical to distinguish TTP from HELLP syndrome as TTP
does not necessarily require pregnancy discontinuation
[8–10] but does require urgent treatment based on
plasma exchange [11]. The annual incidence of ADAMTS-
13 deficiency TMA is less than 2 per million, and is more
common in females [12]. Overall, the estimated incidence
of TTP associated with pregnancy is less than 1 per
100,000 pregnancies [6], and before the era of ADAMTS-
13 assays, it was found at a rate of 1 per 25,000 births [13].
The obstetrical incidence of TTP, as defined by a TMA
with a severe ADAMTS-13 deficiency (activity <10 %) [14],
has not been addressed in women during pregnancy or
post-partum because the assay for ADAMST-13 activity
has only recently become available. However, the identifi-
cation of TTP during pregnancy is crucial, since it is asso-
ciated with poor prognosis of both mother and foetus [5,
15]. To date, the assessment of ADAMTS-13 activity in
pregnant women with thrombocytopenia has not been
performed systematically, and the prevalence of TTP in
pregnant women with thrombocytopenia remains uncer-
tain. We conducted a two-year retrospective study at the
Bordeaux University Hospital tertiary obstetrical unit. We
assessed the incidence of TTP based on ADAMTS-13 ac-
tivity in all consecutive pregnant or post-partum women
presenting with thrombocytopenia less than 75 G/L. TTP
patients were identified and followed through their subse-
quent pregnancies.
Methods
Over a 2-year period (2008–2009), all consecutive patients
hospitalized in the obstetrical unit who presented with at
least one platelet count ≤75 G/L in the setting of pregnancy
were considered. This threshold was used as a means
to avoid over- or under-estimating TTP; ADAMTS-13deficiency is associated with severe thrombocytopenia
[16] and gestational thrombocytopenia is usually en-
countered above 70 G/L [7].
ADAMTS-13 activity was investigated in patients with-
out obvious cause for low platelet count. If ADAMTS-13
activity was not previously measured or a historical blood
sample was not available for testing, a new blood sample
was obtained during normal post-partum follow-up.
ADAMTS-13 assessment was performed as part of rou-
tine screening.
ADAMTS-13 functional activity was assessed by full
von Willebrand Factor length technique as reported
[17]. Activity <5 % was defined as a severe deficiency
(activity >50 % is considered normal). ADAMTS-13 inhibi-
tor was determined using a neutralizing inhibitor approach
as previously described [17] and anti-ADAMTS-13 IgG
was determined by ELISA (TECHNOZYME ADAMTS-13
INH, Technoclone, Austria). Our laboratory cut-off for a
positive value was >35 IU/mL.
When ADAMTS-13 deficiency was found in repeated
measures in the absence of inhibitor, genetic analysis
was conducted for the 29 exons of the ADAMTS-13 gene
and the exon-intron junctions as previously described
[18]. These patients were followed prospectively and, dur-
ing subsequent pregnancies, received virally inactivated
fresh frozen plasma: 20–25 ml/kg fortnightly for the first
trimester, weekly during second trimester, and 25–30 ml/
kg weekly or plasma exchange for plasma volume over
1800 ml during the third trimester. Plasma amount was
adapted to maintain normal platelet counts, normal
levels of plasma LDH and haptoglobin. Residual activity
of ADAMTS-13 was measured before each plasma infu-
sion or exchange. Patients did not receive aspirin. New-
born weight percentile was assessed by the AUDIPOG
tool [19].
Placentas were fixed in formalin, paraffin embedded,
and stained by Haematein-Eosin-Safran.
This retrospective study was approved by the Comité
de Protection des Personnes Sud-Ouest et Outre Mer III
(ethics committee). All patients with ADAMTS-13 defi-
ciency provided written informed consent for the publi-
cation of their individual clinical details.
Results and discussion
Characteristics of the patient cohort studied are outlined
in Fig. 1. There were 4,292 deliveries in 2008 and 4,616
in 2009 in the tertiary care obstetrical unit of Hôpital
Pellegrin. Seventy-nine patients presented thrombocy-
topenia ≤75 G/L (43 and 36 in 2008 and 2009, respect-
ively). Overall, 18 patients had a documented cause of low
platelets, 5 with immune thrombocytopenic purpura, 5 with
congenital thrombocytopenia (2 with MYH9 syndrome, 1
with von Willebrand disease 2B), 5 with massive delivery
bleeding, 1 with paroxysmal nocturnal haemoglobinuria,
Fig. 1 Characteristics of the patient cohort studied. In this retrospective analysis, all consecutive pregnant or post-partum patients seen in the
obstetrical tertiary unit of Bordeaux university hospital who presented a platelet count ≤75 G/L were evaluated
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with systemic lupus erythematosus and positive direct
antiglobulin test. Eleven patients were lost to follow-up.
ADAMTS-13 level was measured in 50 patients. One
patient had an ADAMTS-13 activity of 20 % on retro-
spective analysis in the setting of intra-uterine foetal
death due to retro-placental haematoma at 33 weeks of
gestation (WG), with disseminated intravascular coagu-
lation, a known condition of low ADAMTS-13 activity.
She recovered spontaneously, and was lost to follow-up.
Forty-five patients had normal ADAMTS-13 activity
with a mean of 109 %.
Four patients without significant medical history had
undetectable ADAMTS-13 activity in the peripartum
period (Fig. 1). ADAMTS-13 activity assessment was
mostly performed retrospectively from serum samples
initially used for systematic viral serologies during
hospitalization in the obstetrical unit. For some patients,ADAMTS-13 activity had been measured at the nephrolo-
gist post-partum consultation. Obstetric unit practitioners
were unaware of this rare disease at the time patients were
managed, and ADAMTS-13 assessment was not per-
formed during pregnancy. Prior to the current systematic
two year study, only one deficient patient was diagnosed
at the post-partum consultation. Three primipara patients
(Table 1, patients A, B, C) with an initial diagnosis of
HELLP syndrome in the setting of low platelet count, who
were identified the day of admission, were retrospectively
suspected to have a constitutive severe ADAMTS-13 defi-
ciency. This was confirmed on repeated ADAMTS-13
assays showing <10 % activity over multiple years in the
absence of inhibitor. All three patients gave birth prema-
turely by caesarean section in emergency within 24 hours
of hospitalization, with major placental lesions of ischae-
mia for all. The fourth patient (patient D) had a caesarean
delivery for placenta praevia of her 7th pregnancy (gravida
Table 1 Clinical characteristics of four pregnancy-related TTP patients









ADAMTS-13 activity (%) of
patient’s Father/Mother
(N: 50-150 %)
A 24 P0/28WG Male Yes 25 Headache 22/52
1.3-38p (D + 2) Hypertension
Deceased Proteinuria
Uricemia 441
B 29 P0/33WG Male No 25 Headache 59/34
2.2-30p (D0) No hypertension
Deceased No proteinuria
Uricemia 250
C 22 P0/31WG Female Yes 17 Headache 15/43




D 35 P3/35WG Female Yes 24 Hypertension Not Done
2.9-50p (D + 5) Proteinuria
Healthy Uricemia 194
Patients A, B, C were primipara, whereas, patient D was expecting her fourth child. Patients A and B lost their babies in the neonatal period. For patient A, due to
prematurity (enterocolitis at 6 weeks of age) and for patient B, probably because of a coarctation of the aorta and ventricular septal defect (post-partum day 18).
All patients except patient B presented features of preeclampsia. Patient D, who presented post-partum auto-immune TTP, had two ADAMTS-13 activity assessments at
22 and 25 months after delivery which showed 11 % and 40 %, respectively, without inhibitor, but was lost to follow-up
(y.o.: years old; WG: weeks of gestation; G/L: Giga per liter; D: day of delivery)
Delmas et al. BMC Pregnancy and Childbirth  (2015) 15:137 Page 4 of 87 para 3, with previous uneventful pregnancies except
gravid hypertension during her first pregnancy); she had
an episode of TTP on the 5th day post-partum, with pres-
ence of a plasma inhibitor and anti-ADAMTS-13 IgG
antibodies at 70 IU/ml. She had positive anti-nuclear anti-
bodies at 1/500 without anti-dsDNA. Of importance, she
had received betamethasone at 29 WG and 31 WG for
foetal pulmonary maturation because of bleeding. Pa-
tients’ clinical and biological characteristics are summa-
rized in Table 1. All patients had an undetectable serum
haptoglobin level at the time of thrombocytopenia.
Schistocytes on blood smear were almost never assessed
in the study patients. Lactate dehydrogenase (LDH) was
not documented for patient C. LDH was slightly ele-
vated in patients A and B, 1.3- and 2.1-fold over upper
normal limits, and up to 4.0-fold in patient D, although
not assessed daily. LDH/ASAT ratio, which suggests TTP
rather than HELLP syndrome if over 22 [20], was 10, 2,
and 56 for patient A, B, and D, respectively. Mean platelet
count nadir for the 45 patients with ADAMTS-13 activity
over 20 % was higher with mean (range) platelet count
nadir of 53 G/L (16-75). For these patients, only one had a
platelet count under 30 G/L (16 G/L at nadir, ADAMTS-13
activity of 54 %), but she had an uneventful pregnancy with
vaginal delivery at 37 WG and no abnormal LDH, hapto-
globin, or transaminase value. Patients A, B, C recoveredspontaneously from their TMA without plasma infusion
and exhibited normal blood TMA marker values at
post-partum consultation. Patient D had asymptomatic
thrombocytopenia of 46 G/L 23 days post-delivery but
was lost to follow-up.
In subsequent pregnancies patients A and B received
prophylactic plasma infusion, and gave birth to healthy
children. Patient B had 3 pregnancies overall: plasma in-
fusion was initiated at 13 WG of her second pregnancy
(upon retrospective diagnosis of TTP in her first preg-
nancy) and from 4 WG of her third pregnancy. In her sec-
ond pregnancy she gave birth at 35 WG vaginally to a boy
(birth weight 32th percentile), and in her third pregnancy
gave birth at 38 WG vaginally to a girl (birthweight 38th
percentile). ADAMTS-13 activity for patient B’s second
and third babies were 33 % and 38 % after 6 months. The
histopathological analysis of placentas showed an impres-
sive improvement with plasma exposure during these
three successive pregnancies (Fig. 2).
For patient A, similar observations were made; she
received plasma infusion from the start of her second
pregnancy and gave birth by planned caesarean section
at 34 WG + 3 days to a healthy boy (ADAMTS-13 activ-
ity of 62 % at 8 months). Patient A received 3 plasma
exchanges during the month preceding delivery because
she needed large amounts of plasma (≥2 L). Residual
Fig. 2 Patient B placental pathologies over 3 pregnancies with increasing plasma exposure. Placental pathologies of patient B over her three
pregnancies are shown. 1. No plasma infusion in first pregnancy; delivery at 33 WG due to TTP with a significant advance in maturation and villi
infarction over fibrin deposit. 2. Prophylactic plasma infusions from 13 WG in second pregnancy; significant advance in maturation and intervillous
old thrombosis on placental pathology at 35 WG. 3. Plasma infusions from the beginning of her third pregnancy allowed birth at 38 WG and a
placental histology consistent with the term. Second and third pregnancies were uneventful
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therapy to 15 % throughout pregnancy with prophylactic
treatment.
None of patients A, B, or C exhibited thrombophilia or
autoimmunity. Patient A has a brother with ADAMTS-13
activity of 48 %. Patient C has 3 healthy younger sisters,Fig. 3 Patient B pedigree Arrow indicate the proband, patient B. Cercles an
indicate known ADAMTS-13 basal activity. Activity for patient B children wa
for the girl. (IUFD: intrauterine foetal death. PI: plasma infusion, WG: week gtwo are adults with ADAMTS-13 activities of 29 %
and <5 %. Patient B sibling history is detailed in a family
tree (Fig. 3).
Genetic analysis of ADAMTS-13 for patients A, B, C
are shown in Table 2. Patient A presented a heterozy-
gous p.Arg1060Trp isolated mutation (this is patient n°d squares indicate females and males respectively. The percentages
s assessed at respectively 6.5 for the youngest boy and 8 months old
estation)
Table 2 Genetic analysis of three patients with likely constitutive ADAMTS-13 deficiency




Exon/Intron number Mutation (Status) Protein Protein Non acute phase (basal)
A Exon 24 c.3178C > T p.Arg1060Trp pArg7Trp (Htz) 5 %








C Exon 6 c.559G > C (Htz) pAsp187His - <5 %
Intron 8 c.988-2A > C (Htz) not described
Deleterious polymorphism are in italic [22]
Abbreviations: homozygous, Hm; heterozygous, Htz.
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gous status for the p.Arg1060Trp (c.3178C > T) muta-
tion has been reported previously in late onset TTP
triggered by pregnancy [21]. Potential deleterious effects
associated with the p.Pro618Ala polymorphism in combin-
ation with other mutations in patients A and B have been
described (see Table 2) [22]. No mutation was detected in
any of the 29 exons of ADAMTS-13 in patient B, but there
were four apparently homozygous polymorphisms that
suggested a large deletion in one ADAMTS-13 allele. In
concert with previously described polymorphisms occur-
ring in patient B, this deletion may explain the low albeit
detectable ADAMTS-13 activity during her non-pregnant
status. In patient C, ADAMTS-13 was heterozygous for
two mutations, one exon 6 sequence mutation affecting
the protein structure and modifying the biochemical
property of the metalloprotease domain and a second
mutation located in intron 8 within the essential splice
sequence of exon 9. The genetic analysis, clinical pres-
entation, and familial history are indicative of a consti-
tutive ADAMTS-13 deficiency in patients A, B, C.
Obstetrical TTP is probably under-estimated, with an
estimated incidence of <1/25,000 pregnancies [12,13]. In
this study, the incidence for TTP in a tertiary obstetrical
unit was nearly 1/2,000 pregnancies, and 1/20 among
women with a platelet count ≤75 G/L. Despite the recruit-
ment bias of a tertiary obstetrical unit, given our area of
recruitment of 34,000 deliveries per year, we estimate the
prevalence of TTP during pregnancy to be 1/17000 deliv-
eries. This may also be an underestimate as there were 11
of 79 thrombocytopenic patients lost to follow-up. We
confirmed the high rate of constitutive ADAMTS-13 defi-
ciency in patients with obstetrical TTP, as observed by
Moatti et al. in a previous report [18]. We also confirmedthat pregnancy, by increasing the plasma levels of vWF,
may trigger episodes of TTP in otherwise asymptomatic
patients who carry specific ADAMTS-13 mutations, par-
ticularly the p.Arg1060Trp mutation [18, 21].
In this regard, three of our patients with constitutive,
severe ADAMTS-13 deficiency recovered from TTP fol-
lowing delivery, without plasma infusion. Similar patients
with spontaneous resolution of pregnancy-triggered TTP
have been described by Fujimura et al. in Upshaw-
Schulman families [15], and others since then have been
reviewed in Veyradier et al. [5]. However, fatal TTP in the
setting of pregnancy is commonly reported, and prompt
plasma exchange is mandatory [23]. For the clinician,
these observations suggest that thrombocytopenia during
pregnancy requires (as in all thrombocytopenia) an assess-
ment of haemolysis (LDH, haptoglobin) and a blood film
examination. If symptoms consistent with the diagnosis of
HELLP syndrome occur early during pregnancy and/or
with severe thrombocytopenia, especially if there are fea-
tures of placental ischaemia, ADAMTS-13 activity should
be assessed, ideally in the acute phase of TMA. We found
no obvious specific signs to distinguish HELLP from TTP;
and, in the cases reported here, the ratio LDH/ASAT was
not helpful [20], underscoring the possibility of misleading
presentation [24]. Additionally, none of the TTP women
had a history of jaundice, thrombocytopenia, or anaemia,
and women with a severe constitutive deficiency were
asymptomatic when not pregnant.
Identification of ADAMTS-13 deficiency is helpful to
allow specific care [8, 9, 25–28] of this potentially fatal dis-
ease [10, 15, 23, 29–31]. In constitutively deficient women,
as in previous reports, we invariably observed poor out-
comes of pregnancy in the absence of plasma infusion
prophylaxis. It is clear that the earlier plasma infusion is
Delmas et al. BMC Pregnancy and Childbirth  (2015) 15:137 Page 7 of 8started the better the prognosis. The placental pathology
in patient B supports this conclusion. Further studies to
evaluate ADAMTS-13 deficiency in pregnancy and to
identify biomarkers that would distinguish TTP from
HELLP syndrome would be valuable. Until then, even
when TTP presentation is mild, clinicians should ask
for ADAMTS-13 activity analysis during the acute
phase or at the latest, at the post-partum consultation
or preconception consultation for subsequent pregnan-
cies. If TTP is suspected, plasma exchange should be
promptly initiated without waiting for ADAMTS-13
activity results.
Conclusion
Clinicians should be aware of TTP in cases of early on-
set or severe thrombocytopenia during pregnancy, even
if platelets normalize after delivery or if there is only
mild haemolysis. In a tertiary obstetrical unit, The TTP
incidence was more frequent than expected, approaching
1/2000 deliveries, and 1 per 20 thrombocytopenic patients
≤75 G/L. With respect to constitutive TTP, this study sup-
ports ADAMTS-13 activity assessment in the setting of
HELLP syndrome, even done retrospectively, as this can
clarify diagnosis, allowing prevention of maternal morbid-
ity/mortality and leading to successful childbirth.
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